

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



January 2, 2024

**National Stock Exchange of India Limited,
Scrip Symbol: SUNPHARMA**

**BSE Limited,
Scrip Code: 524715**

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is to inform you that Sun Pharmaceutical Industries Limited (which includes its subsidiaries and/or associate companies) [“Company”], has acquired 100% of shares of Libra Merger Ltd., a company incorporated in Israel.

The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, are attached as per **Annexure A**.

This is for your information and record.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Limited

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.

Tel. : (91-22) 4324 4324

Fax : (91-22) 4324 4343

Website: www.sunpharma.com

Email: secretarial@sunpharma.com

CIN: L24230GJ1993PLC019050

**Annexure A**

Disclosure under sub-para (1) i.e. Acquisition(s) (including agreement to acquire) of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
1	Name of the target entity, details in brief such as size, turnover etc.;	Libra Merger Ltd., incorporated on 18 th July 2023 in Israel, having its registered office at 4 Yitzhak Sade St. Tel Aviv, Israel 6777504.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No
3	Industry to which the entity being acquired belongs;	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To facilitate consolidation of business in Israel
5	Brief details of any governmental or regulatory approvals required for the acquisition;	No
6	Indicative time period for completion of the acquisition;	Completed
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash
8	Cost of acquisition or the price at which the shares are acquired;	NIS 10
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	100%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The target company was incorporated on 18 th July 2023 in Israel. As the Company is recently incorporated, other details are not applicable.